- Healthcare tech company, Pacific Knowledge Systems (PKS) has signed two renewal agreements for its clinical support solution, Rippledown
- The renewal agreements are with two long-standing clients- Australian Clinical Laboratories and Healthscope New Zealand
- RippleDown provides healthcare experts with real-time clinical analysis, interpretations and treatment recommendations
- PKS is up 18.2 per cent on the market and is trading for 13¢ apiece
Healthcare tech company, Pacific Knowledge Systems (PKS) has signed two renewal agreements for its clinical decision support solution, Rippledown.
The renewal agreements are with Australian Clinical Laboratories and Healthscope New Zealand.
PKS develops and commercialises subscription-based clinical decision support (CDS) systems that automate the human decision-making process in healthcare organisations.
Rippledown
RippleDown helps provide healthcare experts, mainly pathologists or clinicians, real-time clinical analysis, interpretations and treatment recommendations.
By analysing the patient’s available information, RippleDown is able to provide interpretations and recommendations for that patient.
Australian Clinical Laboratories
PKS has signed a 3-year extension with Australian Clinical Laboratories (ACL) for Rippledown. ACL is Australia’s third largest private pathology provider and has been a customer of PKS since 2002.
PKS’ CEO Ron van der Pluijm is pleased to continue the relationship with its longstanding customer.
“We are looking forward to continuing to assist in delivering better patient outcomes and efficiencies utilising our RippleDown solution,” he said.
Healthscope NZ
The company has also signed a renewal agreement with another longterm customer, Healthscope NZ.
Healthscope NZ has been a customer of PKS since 2009.
“PKS is pleased to continue the close working relationship with Healthscope NZ. We are looking forward to continuing to assist in delivering better patient outcomes and efficiencies utilising our RippleDown solution,” Ron added.
PKS is up 18.2 per cent on the market and is trading for 13¢ apiece at 2:48 pm AEST.